AI Consensus Investment Thesis
Tarsus Pharmaceuticals (TARS) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
BUY$91
+16.1%5-Year
BUY$145
+85.2%Latest flagship insight
Ophthalmic Monopoly Faces Pipeline Absorption Before True Operating Cash Inflection
High consensus confirms XDEMVY commands an unassailable Demodex blepharitis monopoly with 93% gross margins, driving rapid revenue expansion toward commercial profitability. Sharp divergence centers on capital allocation: substantial upfront acquisition outlays, milestone commitments, and share dilution threaten to tax per-share compounding.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Universal Investor (Polymath), Sherlock Holmes (Whistleblower), Elon Musk (Visionary), Warren Buffett (Value Purist), Machiavelli (Insider), Superintelligence (Anthropologist), J.P. Morgan (Titan), Michael Burry (Vulture), Ray Dalio (Strategist). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Tarsus Pharmaceuticals at the forecast anchor (2026-09-18): $18,516 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 80.44 | +3.01% | +3.01% | Third-quarter results confirm robust commercial demand near the upper guidance bound, but integration expenses from recent pipeline acquisitions and share dilution temper immediate valuation multiple expansion. |
| Q1 2027 | 83.29 | +3.54% | +6.66% | Audited full-year results confirm approaching operational breakeven, though seasonal first-quarter insurance deductible resets and elevated research guidance keep equity appreciation at a measured pace. |
| Q2 2027 | 87.49 | +5.05% | +12.04% | Operating leverage accelerates as first-quarter results demonstrate narrowing operating losses, while preliminary Phase 2 pipeline readouts spark renewed institutional confidence in platform durability. |
| Q3 2027 | 90.64 | +3.59% | +16.07% | Prescription depth compounds across eye-care practices and international milestones contribute non-dilutive licensing revenue, buffering the equity against restrictive macroeconomic interest-rate headwinds. |
| Q4 2027 | 95.07 | +4.89% | +21.74% | Delivery of inaugural sustained quarterly operating profitability confirms commercial scalability, prompting systematic multiple expansion as healthcare funds reclassify the company from speculative biotech to commercial compounder. |
| Q1 2028 | 97.62 | +2.69% | +25.02% | Calendar-year financial disclosures confirm strong full-year operating cash generation, though routine annual payer deductible resets and ongoing Phase 3 trial expenses induce brief trading consolidation. |
| Q2 2028 | 102.08 | +4.56% | +30.72% | European regulatory progress and expanding domestic prescriber penetration drive net product revenues past previous highs, confirming that fixed commercial overhead is decoupling from top-line gains. |
| Q3 2028 | 103.42 | +1.32% | +32.44% | Gross-to-net discount friction from annual managed-care negotiations and summer clinic seasonality slightly moderate sequential growth, resulting in flat-to-modest equity consolidation. |
| Q4 2028 | 107.81 | +4.24% | +38.06% | Commercial net product revenues cross an annualized one-billion-dollar run-rate, while steady 93% gross margins generate substantial free cash flow that self-funds expanding clinical commitments. |
| Q1 2029 | 109.78 | +1.83% | +40.58% | Full-year results reflect solid operating cash flow exceeding two hundred million dollars, yet elevated trial spending on late-stage retinal programs temporarily caps rapid per-share earnings growth. |
| Q2 2029 | 115.10 | +4.84% | +47.39% | Core ophthalmic cash generation provides a sturdy financial bridge as investor anticipation builds around pivotal late-stage clinical readouts, supporting disciplined institutional accumulation. |
| Q3 2029 | 119.38 | +3.72% | +52.87% | Pivotal clinical trial data releases for pipeline assets drive event-driven valuation re-rating, validating the strategic transition toward a multi-franchise specialty pharmaceutical enterprise. |
| Q4 2029 | 123.02 | +3.05% | +57.53% | Post-readout digestion and regulatory preparation costs moderately temper sentiment as investors evaluate commercialization budgets and milestone obligations against available operating cash balances. |
| Q1 2030 | 125.95 | +2.38% | +61.28% | Reporting confirms durable cash compounding from the primary commercial asset, reassuring market participants that corporate operations remain self-funding without reliance on expensive debt markets. |
| Q2 2030 | 128.96 | +2.39% | +65.14% | Supplemental indication filings and label expansion milestones broaden the addressable market, driving operating leverage as new revenues utilize established eye-care sales infrastructure. |
| Q3 2030 | 132.17 | +2.49% | +69.25% | International commercial royalties from Europe and Asia begin flowing into operating income with negligible capital intensity, sustaining earnings compounding despite broader macroeconomic dispersion. |
| Q4 2030 | 136.11 | +2.98% | +74.29% | Accumulating cash reserves prompt board authorization of capital return frameworks, reinforcing an earnings-based valuation floor as commercial maturity shifts focus to owner earnings yields. |
| Q1 2031 | 138.35 | +1.65% | +77.17% | Routine early-year payer formulary true-ups and patent duration reviews slightly moderate multiple expansion, keeping equity valuation tightly tethered to delivered free cash flow. |
| Q2 2031 | 141.82 | +2.51% | +81.62% | Predictable cash flows from mature ophthalmic market penetration and secondary pipeline contributions generate steady earnings per share growth, attracting value-oriented institutional capital. |
| Q3 2031 | 144.59 | +1.95% | +85.16% | The company concludes the forecast horizon as an entrenched specialty pharmaceutical cash generator, trading in valuation equilibrium supported by strong cash yields and long-duration patent protection. |
The base-case thesis rests on an entrenched commercial monopoly in Demodex blepharitis, where XDEMVY leverages routine optometric collarette screening across 25 million addressable hosts. Software-like 93% gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry generate extreme operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry, turning trailing free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry positive and funding baseline operations. However, valuation sensitivity is governed by capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry: the recent acquisitions of Alkeus and iRenix commit over $300 million in upfront cash, expand pro forma shares, and create $537 million in contingent milestone claims alongside nearly doubled R&D guidance. The strongest counterargument highlights that XDEMVY is an acute six-week regimen rather than an ongoing daily therapy; replenishing the patient funnel demands persistent promotional expenditures that, combined with 45% gross-to-net payer deductions, could delay GAAP margin expansionmargin expansionAn increase in profit as a percentage of revenue.View full glossary entry beyond consensus expectations.
Key insights
- Capital structurecapital structureThe mix of debt and equity used to finance a business.View full glossary entry adjustments reveal that headline enterprise valueenterprise valueA measure of total business value, commonly calculated as equity value plus debt and preferred claims, less cash and cash equivalents.View full glossary entry gains will lag top-line growth due to private placement dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry and milestone claims.
- Unit economicsunit economicsRevenue, variable cost, contribution profit, and acquisition or retention economics measured for one customer, product, transaction, or operating unit.View full glossary entry face continuous customer acquisition friction because finite six-week treatment courses require ongoing diagnostic education rather than providing automatic refills.
- Pipeline optionality in Stargardt disease and Lyme prophylaxis offers transformative upside, but carries demanding clinical attrition hurdles and substantial carrying costs.
Tarsus has created a unique prescription eye drop, XDEMVY, that completely dominates an untreated eye condition affecting millions of Americans. Because the medicine costs pennies to manufacture, each new prescription delivers huge cash profits that have already pushed the business past its early cash-burning phase. However, management has spent hundreds of millions of dollars acquiring risky new retinal drug programs, which raises research expenses, creates future milestone debts, and issues more shares. While the core product is an undeniable commercial success, investors must weigh explosive sales against the heavy costs of funding a broader drug pipeline.
Key insights
- Record sales are real, but issued shares and acquisition debts mean company profits get divided across more pieces.
- Because patients take the medicine for only six weeks, the company must constantly spend marketing dollars to find new patients.
- Expanding into rare retinal diseases could create a second blockbuster, but clinical trials face high failure risks before paying off.
Deep Dive
Consensus views the asset as an uncontested single-product commercial success, celebrating XDEMVY's rapid ramp toward raised 2026 guidance of $685-705 million. Sell-side models extrapolate early prescriber momentum toward a $2 billion peak, treating unprofitability as a transient launch phase. However, the crowd anchors heavily on top-line script trajectories while largely dismissing the cash drain, milestone obligations, and share dilution stemming from recent clinical pipeline acquisitions.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Consensus views the asset as an uncontested single-product commercial success, celebrating XDEMVY's rapid ramp toward raised 2026 guidance of $685-705 million. Sell-side models extrapolate early prescriber momentum toward a $2 billion peak, treating unprofitability as a transient launch phase. However, the crowd anchors heavily on top-line script trajectories while largely dismissing the cash drain, milestone obligations, and share dilution stemming from recent clinical pipeline acquisitions.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates the asset's structural cash generation but misjudges its net investment profile, resulting in slight underpricing offset by capital drag. While consensus treats the company as an unprofitable launch story, trailing free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry has inflected positive at $61.5 million on 93% gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry. The analytical edge lies in recognizing that while operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry is real, pro forma cash is thinner and milestone claims are heavier than headline numbers suggest, meaning per-share compounding will lag enterprise revenue growth.
Repricing Catalyst
What could make the market recognize and close that gap? Sustained GAAP operating profitability across consecutive quarters in 2027 will shatter the cash-burn narrative and force institutional re-rating. Observable confirmation will appear as full-year 2026 reporting verifies XDEMVY revenues exceeding $700 million while SG&A growth decelerates relative to gross profit. This transition will compel generalist funds to re-rate the stock from a speculative clinical biotech to an earnings-driven commercial compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry, provided Phase 2 pipeline readouts confirm manageable ongoing R&D commitments.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Greed
- Volatility
- Moderate
- Cycle position
- Growing Awareness
Sentiment aligns on commercial launch momentum, but diverges sharply regarding corporate cycle positioning. Optimists view the asset as entering an unencumbered operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry inflection, whereas contrarians caution that aggressive pipeline acquisitions reset the cycle toward capital-intensive clinical risk.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry of policy rates near 4.00% and elevated benchmark yields presents a mixed setup. Non-discretionary medical demand and self-funding operating cash flows provide structural insulation from broader consumer slowdowns and debt refinancingdebt refinancingReplacing existing debt with new borrowing, often to change maturity, interest cost, currency, or covenants.View full glossary entry hurdles. However, elevated discount rates compress the valuation multiples assigned to long-duration clinical pipeline assets whose primary cash flows reside beyond 2029.
Advisor Disagreement
What do our AI Advisors disagree about most? The critical analytical debate centers on whether Tarsus represents a self-funding commercial cash compoundercash compounderA business that generates high returns on invested capital and reinvests cash to grow value over time.View full glossary entry or an aggressively dilutive clinical acquirer. Bulls argue that 93% gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and positive trailing free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry of $61.5 million make the commercial engine fully self-sustaining, ensuring rapid operating marginoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry expansion past 30%. Contrarians demonstrate that committing $307.5 million in upfront acquisition cash, doubling R&D guidance, and assuming $537 million in contingent milestones significantly thins post-acquisition liquidity. This disagreement will be resolved by monitoring whether Q1 2027 net product revenues exceed $190 million without requiring additional equity raises.
Base-Case Forces
Event Risk ScoreHigh62/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Demodex standard-of-care category monopoly | Competitive Positioning | +42% | +85% | XDEMVY commands an uncontested commercial monopoly as the sole FDA-approved therapeutic for Demodex blepharitis across 25 million addressable US hosts. Routine slit-lamp collarette screening is doubling high-frequency prescribers, expanding net sales toward guidance of $685-705 million. With patent protection extending to 2038, volume expansion flows directly into cash generation, cementing an impenetrable competitive moateconomic moatCompetitive advantage protecting market share and profitability from rivals.View full glossary entry. |
| Extreme operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry from gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry | Operational Efficiency | +32% | +75% | Manufacturing economics deliver elite 93% gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry, ensuring incremental prescription revenue drops almost entirely into contribution profit. As nationwide optometric sales infrastructure stabilizes, top-line growth outpaces SG&A expansion. Trailing free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry has already inflected positive to $61.5 million, providing the foundation for sustained GAAP operating profitability and explosive earnings compounding. |
| International out-licensing and geographic expansion | Innovation And Product | +18% | +28% | Partner approvals, notably via Grand Pharma in Greater China, alongside planned European submissions unlock large patient populations with zero domestic promotional overhead. Foreign regulatory clearances activate milestone payments and high-margin tiered royalties. These capital-light foreign revenues flow straight to operating income, diversifying cash flows and extending the commercial life cycle. |
| Formulary access and demographic insulation | Sector And Industry | +14% | +20% | Securing preferred formulary access across commercial and Medicare Part D plans insulates prescription volume from consumer discretionaryconsumer discretionarySector classification for non-essential goods sensitive to macroeconomic cycles and consumer spending power.View full glossary entry slowdowns. Demodex prevalence rises sharply with age, transforming ocular mite eradication into a non-cyclical demographic standard of carestandard of careThe accepted medical practice or diagnostic protocol used by clinicians to treat specific patient conditions.View full glossary entry. High insured coverage reduces pharmacy counter abandonment, defending unit volumes through macroeconomic contractions. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Portfolio acquisition cash and milestone drain | Capital Allocation | -20% | -32% | Acquiring Alkeus and iRenix committed $307.5 million in upfront cash and nearly doubled 2026 R&D guidance to $190-210 million to fund Phase 3 retinal trials. Additionally, $537 million in contingent milestone liabilities hangs over future cash flows. Siphoning commercial profits into late-stage clinical programs suppresses near-term net margins and delays capital distributions. |
| Gross-to-net payer rebate compression | Regulatory | -15% | -22% | Pharmacy benefit managers extract statutory rebates and concessions, maintaining gross-to-net deductions between 44% and 45%. As volume scales into broader managed-care and Medicare pools, payer scrutiny threatens to expand rebate leakage beyond 50%. This structural pricing drag depresses net realized price per bottle, requiring higher script volumes merely to preserve revenue projections. |
| Episodic therapy patient acquisition treadmill | Operational Efficiency | -14% | -20% | Because XDEMVY is a finite six-week treatment rather than a chronic daily drop, treated patients rotate off therapy. Tarsus cannot rely on permanent refill annuities and must continually fund costly direct-to-consumer advertising to acquire naive patients. High recurring marketing requirements cap operating marginoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry expansion and expose earnings to promotional fatigue. |
| Elevated discount rates compressing multiples | Macroeconomic And Macrofinancial | -12% | -6.0% | Federal Reserve policy rates near 4.00% and 10-year Treasury yields pressing 5.0% raise equity hurdle rates across biopharma. Higher discount factors compress the present value of long-dated pipeline cash flows, such as the 2029 NORTHSTAR trial. This macro drag imposes a valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry discount, dampening share price gains relative to underlying operational execution. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Pivotal NORTHSTAR trial failure and write-down | 36% | -32% | The acquired asset gildeuretinol could fail to achieve statistical significance on retinal lesion slowing in the 2029 NORTHSTAR readout. Because inherited retinal degenerations carry severe clinical attrition, a trial failure would force immediate impairment of acquisition consideration, destroy market confidence in management's capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry, and collapse valuation back to a single-product baseline. |
| Early generic Paragraph IV patent breach | 22% | -42% | Generic filers could submit Abbreviated New Drug Applications with Paragraph IV certifications challenging lotilaner formulation patents following the expiration of statutory chemical exclusivity in 2028. An adverse court ruling invalidating delivery patents would permit premature bioequivalent entry, gutting XDEMVY's 93% gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and destroying long-term terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry expectations. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| NORTHSTAR Phase 3 Stargardt clinical triumph | 32% | +52% | A decisive efficacy readout from the pivotal Phase 3 NORTHSTAR trial of gildeuretinol in 2029 would establish the first approved oral therapy for Stargardt disease. Addressing 36,000 diagnosed US patients under Orphan Drug status would unlock an immediate $1.5 billion monopoly, transforming Tarsus into a diversified retinal powerhouse and triggering aggressive multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. |
| Strategic mega-pharma commercial buyout | 28% | +48% | A global pharmaceutical major seeking to replenish looming patent cliffs could launch an outright acquisition of Tarsus once sustained operating profitability is demonstrated. XDEMVY's 93% gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and 2038 patent exclusivity offer plug-and-play accretion, allowing an acquirer to eliminate redundant commercial overhead and justify a substantial cash takeover premium. |
Company Financial Analysis
Tarsus Pharmaceuticals Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Tarsus has achieved an impressive commercial breakout with its lead eye drop, XDEMVY. Net sales expanded rapidly to $451 million in 2025 and continued surging through mid-2026, reaching $174 million in the second quarter alone. While aggressive spending on advertising and clinical trials produced headline accounting net losses of $18.55 million, the underlying cash story is far more encouraging. Trailing twelve-month free cash flow inflected to positive $61.5 million, proving that day-to-day product sales generate substantial real cash. However, headline sales figures conceal an important detail: first-half 2026 revenue included a one-time $16.7 million international licensing milestone rather than recurring bottle sales. While recurring commercial demand is undeniably accelerating, future earnings growth will depend heavily on management's ability to control research expenses as guidance projects full-year sales approaching $700 million.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 451.4M | USD -66.4M | USD -22.3M |
| 2024 | USD 183M | USD -115.6M | USD -84.6M |
| 2023 | USD 17.4M | USD -135.9M | USD -123M |
| 2022 | USD 25.8M | USD -62.1M | USD -49.5M |
| 2021 | USD 57M | USD -13.8M | USD 3.2M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
The fundamental profit engine of Tarsus is defined by extraordinary gross margins of 93.2%. Because the chemical solution and eye dropper bottles cost pennies on the dollar to manufacture, almost every additional dollar of net sales represents pure gross profit. Operating margins improved dramatically from deep deficits worse than negative 65% in 2024 to negative 15.7% in 2025 as sales volume diluted overhead. Despite this elite unit profitability, GAAP operating margins remain negative because marketing and administrative expenses reached $150.7 million in the second quarter of 2026. Converting 93% gross margins into lasting bottom-line corporate profits requires prescription growth to naturally outrun commercial direct-to-consumer advertising and newly acquired research commitments.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD -71M | -15.7% | -14.7% |
| 2024 | USD -120.6M | -65.9% | -63.2% |
| 2023 | USD -143.2M | -820.5% | -778.9% |
| 2022 | USD -62.7M | -242.9% | -240.5% |
| 2021 | USD -12.2M | -21.3% | -24.2% |
Balance sheet and leverage
AI Review
On the surface, the balance sheet looks exceptionally liquid, closing the second quarter of 2026 with $449.7 million in cash and marketable securities alongside a low debt-to-equity ratio of 0.27. Management bolstered this liquidity with a $125 million private placement equity financing, giving the company strong short-term solvency and protecting it from high interest rates in credit markets. However, the balance sheet is thinner than headline figures suggest. The upfront cash for the Alkeus and iRenix acquisitions consumed over $300 million after the quarter closed. Furthermore, Tarsus took on roughly $537 million in contingent future milestone obligations tied to regulatory and clinical achievements. The business has adequate runway, but its financial cushion is closely tied to continued commercial execution.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 93.6M | USD 417.3M | USD 90M net cash | 3.85x |
| 2024 | USD 72.5M | USD 291.4M | USD 22.4M net cash | 4.42x |
| 2023 | USD 30.2M | USD 227.4M | USD 194.7M net cash | 6.93x |
| 2022 | USD 20.2M | USD 217M | USD 51.5M net cash | 14.61x |
| 2021 | USD 1.9M | USD 171.8M | USD 169.4M net cash | 15.33x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Physical factory investment is practically non-existent, consuming just 2.18% of revenue in 2025. Tarsus relies on third-party contract manufacturing partners to blend and bottle lotilaner, avoiding the heavy capital expense and depreciation charges of owning industrial manufacturing facilities. This asset-light setup allows the company to direct virtually all available capital into marketing and clinical development. Yet true investment intensity exploded in mid-2026 through strategic corporate dealmaking. Management committed $307.5 million in upfront cash to acquire iRenix and Alkeus Pharmaceuticals, nearly doubling full-year research guidance to $190-210 million. While these purchases add exciting late-stage retinal therapies, they redirect commercial profits into long-duration clinical trials that will not produce commercial revenue until 2029 at the earliest.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 9.9M | USD 64.3M |
| 2024 | USD 1.6M | USD 53.4M |
| 2023 | USD 5.5M | USD 50.3M |
| 2022 | USD 506K | USD 42.6M |
| 2021 | USD 586K | USD 41.7M |
Quarterly Forecast Scenarios
Tarsus Pharmaceuticals Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $73.40 | $81.16 | $83.56 | $750.26 | |
| $70.47 | $84.57 | $89.40 | $736.44 | |
| $74.76 | $89.06 | $95.66 | $743.40 | |
| $71.02 | $92.40 | $100.44 | $755.15 | |
| $72.44 | $97.08 | $107.47 | $776.22 | |
| $66.65 | $99.99 | $116.05 | $787.13 | |
| $63.98 | $105.02 | $124.17 | $802.83 | |
| $64.62 | $107.15 | $130.38 | $812.05 | |
| $61.39 | $112.10 | $138.20 | $839.18 | |
| $57.71 | $114.90 | $149.26 | $850.50 | |
| $59.44 | $121.06 | $158.21 | $872.39 | |
| $60.63 | $126.49 | $164.54 | $885.51 | |
| $58.20 | $131.34 | $172.77 | $909.56 | |
| $56.46 | $134.36 | $183.13 | $916.13 | |
| $57.59 | $138.79 | $192.29 | $936.51 | |
| $56.43 | $142.88 | $198.06 | $947.34 | |
| $58.13 | $147.28 | $205.98 | $969.59 | |
| $56.97 | $150.26 | $216.28 | $979.99 | |
| $58.10 | $154.37 | $222.77 | $999.60 | |
| $58.10 | $157.74 | $231.68 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The common independently supported pattern across the reports confirms commercial hyper-scaling, characterized by net sales reaching $685-705 million in 2026 and pristine gross margins near 93%. However, correlated assumptions frequently overlook how aggressive business development reshapes per-share economics. Reports that naively extrapolate stand-alone cash flow without deducting $307.5 million in upfront acquisition outlays, roughly $537 million in contingent milestones, and equity dilution from private placements receive reduced weight. The strongest credible contrarian insight emphasizes that acute six-week dosing requires continuous customer acquisition outlays, curbing operating leverage. Consequently, top allocations are assigned to opinions providing rigorous capital structure adjustments, accounting for share count expansion and elevated research budgets through the 2029 clinical trial window.
Universal Investor AI
The Polymath
Opus 5Superior evidentiary rigor; explicitly accounts for the $537 million in contingent liabilities, post-acquisition pro forma cash, and the expanded share denominator.
Universal Investor AI
The Polymath
GPT-6 AstraRigorous forensic capital structure audit; incorporates PIPE dilution, acquisition consideration, and pro forma share counts to establish a grounded per-share compounding trajectory.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashPresents sound economic arguments on Demodex prevalence and gross margin durability, but underestimates the capital drain and milestone liabilities introduced by recent corporate pipeline acquisitions.
Elon Musk AI
The Visionary
Gemini 3.8 FlashCorrectly emphasizes 93% gross margins and category creation, yet projects rapid SG&A normalization while discounting post-acquisition R&D guidance increases and share dilution.
Universal Investor AI
The Polymath
Gemini 3.8 FlashProvides balanced modeling of optometric adoption and free cash flow inflection, though it slightly understates the balance sheet commitment required for late-stage retinal trials.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashGrounds the commercial trajectory in verified 2026 guidance metrics, offering a balanced view of optometric adoption alongside realistic payer gross-to-net deduction pressures.
Michael Burry AI
The Vulture
Gemini 3.8 FlashProvides a crucial contrarian perspective on acute therapy churn and rising customer acquisition costs, although it somewhat overstates terminal unit-economic decay given recurring infestation dynamics.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashCaptures standard-of-care entrenchment and high gross contribution, but relies on overly aggressive multiple expansion targets that overlook prevailing cost-of-capital constraints.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashOffers compelling analysis of unit-level owner economics and intellectual property duration, yet assumes an optimistic free-cash conversion timeline by downplaying R&D step-ups.
Universal Investor AI
The Polymath
Gemini 3.8 FlashDemonstrates solid understanding of high contribution margins and operating leverage, but its multi-indication timeline assumes smooth clinical execution across adjacent pipelines.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashArticulates a clear consolidation thesis modeled on specialty pharma dynasties, but projects an excessively aggressive multi-billion equity expansion that minimizes clinical trial failure risks.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashHighlights Orange Book patent barriers through 2038 and managed care dynamics well, but underweights the immediate cash absorption of pivotal Phase 3 trials.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashSound breakdown of gross profitability and pricing power, but exhibits redundant assumptions regarding commercial multiple expansion under restrictive monetary conditions.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashDetailed overview of operating leverage, but models a sudden outlier jump in late 2029 returns that is uncorroborated by broader clinical pipeline timelines.
Research Provenance
References & Context
This Tarsus Pharmaceuticals consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 49 deduplicated sources retained for this batch.
- 01Drug Trials Snapshots: XDEMVY | FDAfda.gov
- 02Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
- 03tars-20251231sec.gov
- 04tars-20260904sec.gov
- 05Tarsus Pharmaceuticals, Inc. - Form 10-Q - FY2026sec.gov
- 06Tarsus Pharmaceuticals, Inc. - Form 8-K - FY2026sec.gov
- 07Tarsus Pharmaceuticals, Inc. - Form 8-K - FY2026sec.gov
- 08Tarsus (TARS) Q2 2026 Earnings Call Transcript - AOLaol.com
- 09TARS Stock Quote Price and Forecast | CNNcnn.com
- 10Tarsus Pharmaceuticals Inc (TARS) (Q2 2026) Earnings Call Highlights: Record XDEMVY Sales and ...finance.yahoo.com
- 11Tarsus Pharmaceuticals Q2 Earnings Call Highlightsfinance.yahoo.com
- 12Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Careglobenewswire.com
- 13Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Careglobenewswire.com
- 14Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growthglobenewswire.com
- 15Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis | Tarsus Pharmaceuticalsir.tarsusrx.com
And 34 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
4 fieldscapitalExpenditures · freeCashFlow · salePurchaseOfStock · totalCashFromOperatingActivities
annual: 2018-12-31–2025-12-31, 8 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.